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Regnase-1 (also known as Zc3h12a and MCPIP1) is
an RNase that destabilizes a set of mRNAs, including
Il6 and Il12b, through cleavage of their 30 UTRs.
Although Regnase-1 inactivation leads to develop-
ment of an autoimmune disease characterized by
T cell activation and hyperimmunoglobulinemia in
mice, the mechanism of Regnase-1-mediated
immune regulation has remained unclear. We show
that Regnase-1 is essential for preventing aberrant
effector CD4+ T cell generation cell autonomously.
Moreover, in T cells, Regnase-1 regulates themRNAs
of a set of genes, including c-Rel, Ox40, and Il2,
through cleavage of their 30 UTRs. Interestingly,
T cell receptor (TCR) stimulation leads to cleavage
of Regnase-1 at R111 by Malt1/paracaspase, freeing
T cells from Regnase-1-mediated suppression.
Furthermore, Malt1 protease activity is critical for
controlling the mRNA stability of T cell effector
genes. Collectively, these results indicate that
dynamic control of Regnase-1 expression in T cells
is critical for controlling T cell activation.
INTRODUCTION
Immune cell activation is accompanied by dynamic changes
in expression of genes related to inflammation (Beutler, 2009;1036 Cell 153, 1036–1049, May 23, 2013 ª2013 Elsevier Inc.Iwasaki and Medzhitov, 2010; Takeuchi and Akira, 2010).
Concomitantly, immune reactions are tightly controlled to pre-
vent harmful pathologies, such as septic shock or autoimmune
disease, due to sustained inflammation. Gene expression is
controlled at multiple checkpoints, including signal transduction,
transcription, and messenger RNA (mRNA) stability. Among
these, transcriptional regulation has been studied extensively
in the context of immune responses (Vallabhapurapu and Karin,
2009). Transcription factors, such as NF-kB and AP-1, are
sequestered in the cytoplasm in resting immune cells and trans-
locate to the nucleus in response to various stimuli, such as Toll-
like receptor (TLR) ligands, Tumor necrosis factor (TNF), and
Interleukin-1b (IL-1b) in innate immune cells, and antigen recep-
tor stimulation in acquired immune cells (Hayden and Ghosh,
2008). Nuclear NF-kB and AP-1 are, in turn, responsible for tran-
scriptional activation of a set of genes controlling inflammation.
Thus, signal-induced transcriptional activation is a common
feature of both innate and acquired immunity.
On the other hand, recent studies have revealed that control of
gene expression at the mRNA level is as important as transcrip-
tional control (Anderson, 2008; Hao and Baltimore, 2009). It is
widely accepted that microRNA is critical for fine-tuning immune
reactions, both in innate and adaptive immune cells (O’Connell
et al., 2010; O’Neill et al., 2011). Furthermore, a set of RNA bind-
ing proteins has been shown to be important for controlling the
stability of mRNAs related to immune activation, such as cyto-
kines. For instance, tristetraprolin, a protein with tandem
CCCH-type zinc-finger motifs, destabilizes TNF mRNA by bind-
ing with AU-rich elements present in its 30 UTR (Carballo et al.,
1998). Furthermore, another CCCH-type zinc-finger molecule,
Roquin, is critical for suppressing expression of mRNA encoding
Inducible T cell coactivator (Icos) by binding to its 30 UTR (Glas-
macher et al., 2010; Vinuesa et al., 2005) or through a microRNA
(Yu et al., 2007). A point mutation in Roquin resulted in
augmented expression of ICOS on follicular helper T cells, lead-
ing to an autoimmune disease by facilitating the production of
autoantibody-producing B cells (Linterman et al., 2009). Thus,
regulation of mRNA decay is critical for suppressing aberrant
activation of not only innate immune cells but also acquired
immune cells, including T cells.
We have previously shown that a set of mRNAs, including Il6
and Il12b, is destabilized by a novel ribonuclease (RNase) named
Regnase-1 (also known as Zc3h12a andMCPIP1) in response to
TLR ligands in macrophages (Matsushita et al., 2009). Further-
more, we found that Regnase-1 is phosphorylated by IkB
kinases (IKKs) in response to TLR ligands or IL-1b stimulation
via the MyD88-dependent signaling pathway, leading to rapid
degradation of Regnase-1 in an ubiquitin/proteasome-depen-
dent fashion (Iwasaki et al., 2011). The degradation of Reg-
nase-1 releases the ‘‘brake’’ on Il6 mRNA expression and
enables rapid and robust induction of Il6 mRNA when needed.
Interestingly, Regnase-1-deficient mice showed severe sys-
temic inflammation characterized by T cell and B cell activation.
These mice also showed hyperimmunoglobulinemia and pro-
duced autoantibodies. However, the induction mechanism of
these inflammatory diseases is not well understood. Moreover,
in addition to macrophages, Regnase-1 is expressed in various
immune cells, including T and B cells.
In this study, we investigated the role of T cells in the induction
of autoimmune disease in Regnase-1-deficient mice by gener-
ating a conditional Regnase-1 allele. T-cell-specific deletion of
Regnase-1 induces T andBcell activation aswell as the develop-
ment of autoimmune disease. Regnase-1 was degraded in
response toT cell receptor (TCR) stimulation in amanner different
from that in response to TLR/IL-18R stimulation. Malt1 cleaves
Regnase-1 at R111 in response to TCR stimulation, and the pro-
tease activity of Malt1 is necessary for prolonging the half-life of
Regnase-1 target mRNAs. Thus, Regnase-1 is critical for pre-
venting autoimmunity in a resting T-cell-intrinsic manner and is
dynamically regulated in the course of T cell activation.
RESULTS
Lack of Regnase-1 in T Cells Recapitulates Autoimmune
Disease in Regnase-1/ Mice
To investigate the role of IL-6 in the development of autoim-
mune inflammatory disease in the absence of Regnase-1, we
generated mice lacking both Regnase-1 and IL-6. The massive
increase in splenic plasma cells and immunoglobulinM/immuno-
globulin D (IgM/IgD) double-negative B cells observed in
Regnase-1/ mice was reduced in mice lacking both Reg-
nase-1 and IL-6 (Figures S1A and S1B available online). In
contrast, generation of effector/memory T cells was unchanged,
even in the absence of IL-6 (Figure S1C). Furthermore, deficiency
in the IL-12p40 subunit did not change the accumulation of
plasma cells or the activation of T cells (Figures S1D and S1E),
though Th1 cell development and production of IFN-g required
IL-12 (Figures S1F and S1G). These results demonstrate thatactivation of T cells in Regnase-1/ mice cannot be explained
simply by the overproduction of a set of cytokines. Because
we have previously shown that Regnase-1 is expressed in
various hematopoietic cells, such as T cells and B cells (Iwasaki
et al., 2011), we hypothesized that Regnase-1 acts cell autono-
mously in T cells. To examine the role of Regnase-1 in lympho-
cytes, we established floxed Regnase-1 (Regnase-1fl/fl) mice
(Figure S2A). The mice were crossed with mice expressing Cre
under the control of a CD4 promoter (CD4-Cre). Recombination
of the Regnase-1 locus in CD4-Cre+Regnase-1fl/fl T cells was
confirmed by Southern blot analysis (Figures S2B and S2C).
An immunoblot analysis showed abrogation of Regnase-1
expression in T cells, but not in B cells (Figure S2D).
Interestingly, CD4-Cre+Regnase-1fl/fl mice started to die
8 weeks after birth, and most of them died within 17 weeks (Fig-
ure 1A). T-cell-specific deletion of Regnase-1 led to the develop-
ment of severe splenomegaly (Figure 1B). The total numbers of
splenic T cells were elevated, and most splenic T cells from
CD4-Cre+Regnase-1fl/fl mice were CD62LCD44hi effector/
memory T cells (Figure 1C). Splenic T cells stimulated with anti-
CD3ε and/or anti-CD28 antibodies, and phorbol myristate ace-
tate (PMA) plus ionomycin had elevated production of IFN-g,
IL-17, and IL-4 (Figures 1D and 1E), suggesting that T cells
were polarized to various helper T cell subsets. Regnase-1/
CD4+ andCD8+ T cells showed elevated expression of Ki67, indi-
cating that Regnase-1-ablated T cells exhibit accelerated cell-
cycle progression (Figure 1F). Consistent with T cell activation,
CD19dullCD138hi plasma cells accumulated more in CD4-Cre+
Regnase-1fl/fl mice than in control mice (Figure 1G). Furthermore,
most of CD19+ B cells did not express IgM or IgD (Figure 1H). All
subtypes of immunoglobulins were highly elevated in the sera of
CD4-Cre+Regnase-1fl/fl mice (Figure 1I), and anti-nuclear anti-
bodies were also detected (Figure 1J). To further confirm that
Regnase-1 in T cells are responsible for the pathology, we
crossed floxed Regnase-1 mice with Lck-Cre mice, which
express Cre in T cells from early in the thymic T cell development
(Figure S2E). Lck-Cre+Regnase-1fl/flmice also showed amassive
increase in effector CD4+ T cells (Figure S1H), and elevation of
plasma cells as well as class switched B cells (Figure S1I). These
data indicate that deletion of Regnase-1 in T cells led to the
development of a severe autoimmune inflammatory disease.
Peripheral CD4+ T Cell Activation Is Sufficient for the
Pathology in CD4-Cre+ Regnase-1fl/fl Mice
We next investigated thymic T cell development in CD4-Cre+
Regnase-1fl/fl mice. The subsets of thymic T cells as well as
splenic CD4+ and CD8+ subsets were indistinguishable
between CD4-Cre+ Regnase-1fl/fl and control mice (Figures S3A
and S3B). Furthermore, the TCRb repertoire of peripheral CD4+
T cells was comparable between CD4-Cre+Regnase-1fl/fl and
control mice (Figure S3C). These results suggest that thymic
T cell development is not affected by deletion of Regnase-1 in
T cells. To further investigate whether peripheral CD4+ T cells
are pathogenic in CD4-Cre+Regnase-1fl/fl mice, we transferred
splenic CD4+ T cells from CD4-Cre+Regnase-1fl/fl or control
mice into congenic CD45.1+ mice. Mice that received Regnase-
1-deficient CD4+ T cells showed severe splenomegaly (Fig-
ure 2A). CD4+ T cells from CD4-Cre+Regnase-1fl/fl mice survivedCell 153, 1036–1049, May 23, 2013 ª2013 Elsevier Inc. 1037
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Figure 1. T-Cell-Specific Deletion of Regnase-1 Causes Autoimmune Inflammatory Disease in Mice
(A) Survival rates of control (CD4-Cre+ Regnase-1+/+ or fl/+) and CD4-Cre+ Regnase-1fl/fl mice at the indicated periods (n = 20).
(B) Spleens from three representative mice with the indicated genotype.
(C) Flow cytometric analysis of expression of CD62L and CD44 in splenic CD4+ and CD8+ T cells.
(D) Production of IFN-g in response to CD3ε and CD28, and PMA plus ionomycin in splenic T cells. Error bars indicate SD of triplicates.
(E and F) Intracellular staining of IFN-g, IL-4, and IL-17 in splenic CD4+ T cells after stimulationwith PMA and ionomycin (E), and expression of Ki67 in splenic CD4+
and CD8+ unstimulated T cells (F).
(G and H) Flow cytometric analysis of proportion of plasma cells in the spleen (G) and expression of IgM and IgD in splenic CD19+ B cells (H).
(legend continued on next page)
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for 3 months in the recipient mice, although CD4+ T cells from
control mice were not detected (Figure 2B). Surprisingly, transfer
of splenic CD4+ T cells from CD4-Cre+Regnase-1fl/fl mice alone
led to the increase of recipient CD45.1+CD62loCD44hi effector/
memory T cells as well as CD19dullCD138hi plasma cells (Figures
2C and 2D). These results indicate that Regnase-1/ peripheral
CD4+ T cells have the ability to activate immune cells. Next, we
utilized the IFN-inducible Cre-expressing system (Mx-Cre).
Treatment of Mx-Cre+Regnase-1fl/fl mice with polyinosinic:poly-
cytidylic acid (poly I:C) rapidly reduced Regnase-1 expression
(Figure S2F), followed by an accumulation of CD44hi CD4+
Tcells in theblood (Figure 2E). In contrast, poly I:C did not change
CD44hi T cells in control mice. Then CD4+ T cells isolated from
untreated Mx-Cre+Regnase-1fl/fl or control spleen were trans-
ferred into CD45.1+ mice, and recipient mice were immediately
treated with poly I:C (Figure 2F). CD4+ T cells that lost Reg-
nase-1 expression peripherally survived for 3 months in the
spleen (Figure 2G). Furthermore, the mice showed increased
levels of CD45.1+CD62loCD44hi effector/memory T cells and an
accumulation of CD19dullCD138hi plasma cells (Figures 2H and
2I). The proportion of FoxP3+CD4+ regulatory T (Treg) cells was
comparable between control and CD4-Cre+Regnase-1fl/fl
splenocytes (Figure S3D). In addition, Treg cells purified from
Mx-Cre+Regnase-1fl/fl splenocytes 10 days after poly I:C treat-
ment were competent in suppressing effector T cells, suggesting
that Treg cells are not functionally defective in the absence of
Regnase-1 (Figure S3E). These results demonstrate that Reg-
nase-1 plays a pivotal role in preventing aberrant generation of
effector CD4+ T cells peripherally in a cell-autonomous fashion.
Recognition of Antigens by TCR Is Required for
Pathology under Regnase-1-Deficient Conditions
To examine the requirement of TCR-mediated antigen recogni-
tion in T cell activation under Regnase-1-deficient conditions,
we generated Regnase-1-deficient mice harboring a TCR spe-
cific to ovalbumin (OVA) in CD4+ T cells (OT-II+Regnase-1/).
Surprisingly, Regnase-1-deficient T cells stained with an I-Ab
OVA323-339 tetramer showed a CD62L
hiCD44lo-naive phenotype
(Figure 2J), indicating that aberrant activation of T cells under
Regnase-1-deficient conditions requires TCR signaling. Further-
more, immunization of Regnase-1-deficient mice harboring
OVA-specific CD4+ T cells resulted in a highly enhanced transi-
tion of naive to effector/memory CD4+ T cells (Figure 2K). To
further investigate whether the aberrant activation is T cell
intrinsic, we adoptively transferred OT-II+Regnase-1/-naive
CD4+ T cells into CD45.1+ congenic mice. Five days after immu-
nization with OVA with aluminum adjuvant (Alum), the number of
CD45.2+ OT-II+ cells lacking Regnase-1 was about 3- to 6-fold
higher than that of OT-II+ control cells (Figure 2L). Thenwe exam-
ined the effector responses of OT-II+ T cells by recall assay
in vitro after stimulation with OVA323-339 peptide. Splenocytes
from mice receiving OT-II+ T cells lacking Regnase-1 showed
highly enhanced proliferative responses (Figure 2M) and produc-(I) Hypergammaglobulinemia in CD4-Cre+ Regnase-1fl/fl mice. Serum immunoglo
(J) Production in antinuclear antibodies (ANA) in CD4-Cre+ Regnase-1fl/fl mice.
Bars indicate themean, and statistical significancewas determined using the Stud
three (D and E), or five (C, G, and H) independent experiments. See also Figurestion of IFN-g (Figure 2N) than mice receiving control cells. These
results demonstrate that Regnase-1 is critical for suppressing
excess immune responses in T cells downstream of the TCR.
A Set of Effector Genes Is Highly Expressed in CD4+ T
Cells Lacking Regnase-1
To understand the molecular basis for pathogenicity of CD4+
T cells under Regnase-1 deficiency, we examined gene expres-
sion profiles in CD4+ T cells from CD4Cre+-Regnase-1fl/fl and
control mice. We found that Regnase-1 deficiency in CD4+
T cells upregulated the expression of many genes (Figure 3A;
Table S1) (424 genes were upregulated more than 10-fold under
Regnase-1 deficiency, in contrast to 157 genes downregulated
in the cells). Among the genes involved in T cell activation, Reg-
nase-1 deficiency increased the expression of surface mole-
cules, including Icos, Tnfr2, Ox40, and Il2rb1, and cytokines,
such as Il6 and Il2 (Table S1). The transcriptome data were
confirmed by quantitative PCR analysis (Figure 3B), and surface
expression of T cell activation markers, including ICOS, CD40L,
TNFRII, OX40, IL-2Ra, CD69, and CTLA4, but not CD28, were
highly upregulated in CD4+ T cells from CD4-Cre+Regnase-1fl/fl
mice compared with wild-type (Figure 3C). T cell activation is
known to be regulated by a set of transcription factors belonging
to the NF-kB and NF-AT families (Rao et al., 1997; Sun et al.,
2000). When we checked the expression of genes in these tran-
scription factor families, the expression of c-Rel mRNA was
higher in T cells lacking Regnase-1 compared with control cells.
On the other hand, the expression of other NF-kB members and
NF-ATc1 were not altered between control and Regnase-1/
T cells, based on the transcriptome analysis. Furthermore,
c-Rel, but not RelA, was more abundantly expressed in the
absence of Regnase-1 even at the protein level in whole-cell
lysates and in nuclear proteins (Figure 3D). These results indicate
that c-Rel is negatively regulated by Regnase-1.
To exclude the possibility that the difference in the gene
expression is simply due to the difference in the proportion of
naive and effector CD4+ T cells in the absence of Regnase-1,
we sorted CD62LhiCD44lo and CD62LloCD44hi CD4+ T cells
from Mx-Cre+Regnase-1+/+ and Mx-Cre+Regnase-1fl/fl mice
10 days after poly I:C treatment. At this period, more numbers
of CD62LhiCD44lo-naive CD4+ T cells remained in Mx-Cre+
Regnase-1fl/fl mouse splenocytes (Figure S4A). We examined
the gene expression in the sorted cells by a microarray analysis.
The expression of c-Rel and a set of costimulatory molecules
were elevated both in naive and effector CD4+ T cells from
Mx-Cre+Regnase-1fl/fl mice (Figure S4B; Table S2).
Then we examined the role of Regnase-1 in the TCR signaling
pathways. First, the levels of TCRb expression on the cell surface
were not altered even in the absence of Regnase-1 (Figure S4C).
TCR-induced tyrosine phosphorylation was not enhanced even
in the absence of Regnase-1 in OT-II+CD4+ T cells (Figure S4D).
Furthermore, MAP kinase activation or the NF-ATc1-DNA bind-
ing activity to TCR stimulation was not increased in the absencebulin levels were measured.
ent’s t test in (I) and (J). *p < 0.01, **p < 0.001. Data are representative of two (F),
S1 and S2.
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(A) Spleens from mice that received CD4+ T cells from control or CD4-Cre+ Regnase-1fl/fl mice.
(B–D) Representative flow cytometric analysis of splenocytes. Splenic CD4+ T cells from CD4-Cre+ Regnase-1fl/+ or CD4-Cre+ Regnase-1fl/fl mice were trans-
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of Regnase-1 (Figures S4E and S4F). Whereas many genes
upregulated in T cells lacking Regnase-1 are known to be regu-
lated by NF-kB, activation of the NF-kBp65 subunit in response
to stimulation with anti-CD3ε Ab and PMA plus ionomycin was
not enhanced, but impaired, in the absence of Regnase-1 in
CD4+ T cells (Figure S4G). In contrast, OT-II+ splenic T cells lack-
ing Regnase-1 showed enhanced proliferation compared with
wild-type OT-II+ T cells in response to anti-CD3ε Ab stimulation
(Figure S4H). Furthermore, TCR-induced production of effector
cytokines, such as IFN-g, IL-17, and IL-4, was also elevated in
the absence of Regnase-1 (Figure S4I). Collectively, Regnase-1
suppresses T cell effector functions downstream of the TCR
signaling pathways.
Furthermore, we knocked down Regnase-1 expression in
Jurkat cells (Figure 4A) and examined changes in mRNA
expression in response to PMA and ionomycin stimulation.
Knockdown of Regnase-1 increased expression of c-Rel,
Ox40, and Il2 mRNA after stimulation with PMA plus ionomycin
(Figure 4B). In contrast, IkBa mRNA levels were comparably
induced between parent and Regnase-1 knockdown Jurkat
cells. Furthermore, the half-lives of c-Rel, Ox40, and Il2
mRNA, but not IkBa mRNA, were extended in Regnase-1
knockdown cells compared to cells treated with control small
interfering RNA (siRNA) (Figure 4C). Reciprocally, overexpres-
sion of Regnase-1 in Jurkat cells resulted in the inhibition of
the expression of c-Rel, Ox40, and Il2 mRNA (Figure 4D). In
contrast, the expression of Regnase-1 RNase-inactive form
(D141N) failed to suppress these mRNAs, indicating that the
RNase activity of Regnase-1 is essential for suppressing a set
of mRNAs.
We have previously shown that Regnase-1 controls the
expression of mRNAs via their 30 UTR. To examine whether
mRNAs encoding proteins controlling T cell activation are regu-
lated by Regnase-1, we generated a set of luciferase reporter
constructs with 30 UTRs from genes encoding cytokines, cell-
surface molecules, and transcription factors. By coexpression
of these reporters and Regnase-1 or its nuclease-inactive form
in HEK293 cells, we could identify genes whose 30 UTRs are
regulated by Regnase-1 nuclease activity. In addition to Il6 and
Il12b, Il1b and Il2 are destabilized by Regnase-1 overexpression
(Figure S5A). When we examined cell-surface molecules
involved in T cell activation, Icos, Cd44,Ox40, and Tnfr2mRNAs
were downregulated by Regnase-1 expression (Figure S5B),
consistent with upregulation of these genes in T cells lacking(E) Percentage of CD44hi among CD4+ T cells in the blood from Mx-Cre+ Regnas
indicate SD.
(F) Schematic diagram of generation of mice transferred with CD4+ T cells from
(G–I) Flow cytometric analysis of splenocytes of the mice transferred as in (F). Po
CD44 (H) in CD45.1+CD4+ T cells, and proportion of plasma cells (I).
(J and K) Flow cytometric analysis of splenocytes of the mice with the indicated ge
immunization (K).
(L–N) OT-II+ control or Regnase-1-deficient naive CD4+ T cells were adoptively
number of OVA-induced donor CD4+ T cells was examined, and FACS analysis w
after immunization (L). Bars indicate the means and statistical significance was d
various doses of OVA peptide, and recall proliferation was assessed by thymid
pernatant at 48 hr (N). Error bars indicate SD.
Open and closed circles represents OT-II+ control (n = 8) and Regnase-1-deficien
two independent experiments. See also Figure S3.Regnase-1. Among transcription factors involved in T cell activa-
tion, c-Rel mRNA 30 UTR was profoundly inhibited by wild-type,
but not D141N, Regnase-1 expression (Figure S5C). In contrast,
the 30 UTR of NF-kB family members other than c-Rel were
unaffected by Regnase-1 overexpression (Figure S5C), indi-
cating that c-Rel is the sole Regnase-1 target among NF-kB
family members. Although NFATc1 mRNA 30 UTR was inhibited
by Regnase-1 overexpression, NFATc1 mRNA expression was
increased only modestly in the absence of Regnase-1 in
T cells (Figure S5D; Table S1). Collectively, Regnase-1 appears
to control multiple mRNAs for suppressing T cell effector
function.
To examine whether mRNAs differentially expressed in Reg-
nase-1-deficient T cells are directly regulated by Regnase-1,
we examined mRNAs encoding Il2, Ox40, and c-Rel. The Tet-
off assay revealed that overexpression of wild-type, but not
D141N mutant, Regnase-1 accelerated the degradation of Il2,
Ox40, and c-Rel mRNAs (Figure 4E), which indicates that Reg-
nase-1 directly destabilizes Il2, Ox40, and c-Rel mRNAs in a
manner dependent on their RNase activity. Then we examined
sequences responsible for Regnase-1-mediated suppression in
c-Rel 30 UTR. We transfected HEK293 cells with luciferase
reporter constructs with the 30 UTR of c-Rel. In addition to
the entire 30 UTR of c-Rel mRNA, the first half of the 30 UTR
recapitulates Regnase-1-mediated suppression (Figure 4F).
We found putative stem-loop structures in the sequences of
the first half of c-Rel 30 UTR (Figure 4G). Addition of these
sequences from the c-Rel 30 UTR to b-globin 30 UTR resulted
in reduction of the luciferase activity in response to Regnase-1
overexpression (Figure 4F), suggesting that this stem-loop
structure is responsible for Regnase-1-mediated inhibition of
c-Rel expression.
Deletion of c-Rel Partially Rescued T Cell Effector
Function in Regnase-1/ Mice
Given that some of the genes upregulated in Regnase-1-defi-
cient T cells are not direct Regnase-1 targets, we hypothesized
that transcription factor(s) regulated by Regnase-1 further con-
trol T cell activation. c-Rel has been shown to be a key factor
in T cell activation associated with autoimmune disease (Hilliard
et al., 2002). Therefore, we generated mice lacking both c-Rel
and Regnase-1. The differentiation of CD4+ T cells from naive
to effector/memory cells as well as surface CD69 expression
observed in Regnase-1/ mice was partially inhibited by thee-1fl/+ or Mx-Cre+ Regnase-1fl/fl after treatment with poly I:C (n = 3). Error bars
Mx-Cre+Regnase-1fl/+ or Mx-Cre+Regnase-1fl/fl.
pulation of CD45.1 and CD45.2 in CD4+ T cells (G), expression of CD62L and
notype. Expression of CD62L and CD44 without treatment (J) and 1 week after
transferred to CD45.1+ wild-type mice and immunized with OVA in Alum. The
as performed using pooled populations of splenocytes and LN cells at day 5
etermined using the Student’s t test in (L). Splenocytes were restimulated with
ine incorporation at 72 hr (M). IFN-g production was measured in culture su-
t (n = 6) CD4+ T cells, respectively. *p < 0.001. Similar results were obtained in
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Figure 3. Altered Gene Expressions of Cytokines, Surface Costimulatory Molecules, and Transcription Factors in the Absence of Regnase-1
(A) Scatterplot of gene expression profile in CD4+ T cells from wild-type and CD4-Cre+Regnase-1fl/fl mice. The red, orange, yellow, and blue lines represent 100-,
10-, 5-, and 2-fold differences, respectively.
(B) Quantitative PCR analysis of the expressions of a set of genes in splenic CD4+ T cells from mice with the indicated genotype. Error bars indicate SD.
(C) Expression of surface markers in CD4+ T cells from mice with the indicated genotype.
(D) Immunoblot analysis of whole-cell lysate and nuclear extract of control orRegnase-1/ T cells. The protein levels of c-Rel and p65were quantified as a ratio to
a loading control by densitometry.
See also Figure S4 and Tables S1 and S2.lack of c-Rel (Figures S6A and S6B). Furthermore, generation of
CD138+ plasma cells depends on the presence of c-Rel (Fig-
ure S6C). Because the levels of c-Rel expression was partially
reduced in Rel+/ T cells compared with wild-type (Figure S6D),
we examined the effect of the decrease of c-Rel expression in
Regnase-1 deficiency by generating Regnase-1/Rel+/ mice.1042 Cell 153, 1036–1049, May 23, 2013 ª2013 Elsevier Inc.Indeed, decrease, but not abrogation, of c-Rel also partially
rescued the increase of effector T cells and plasma cells and
surface expression of CD69 induced by Regnase-1 deficiency
(Figure S6E). These results indicate that increased c-Rel expres-
sion contributes to the activation of T cells and subsequent B cell
activation under Regnase-1 deficiency.
AB
C
D
E
F G
Figure 4. Identification of Regnase-1 Target mRNAs in T Cells
(A) Immunoblot analysis of Regnase-1 in Jurkat cells transfected by electroporation with Regnase-1-specific siRNA (si-Reg1) and control siRNA (si-Cont).
(B) Quantitative PCR analysis of mRNAs encoding c-Rel,Ox40, Il2 and IkBa in Jurkat cells electroporatedwith si-Reg1 or si-Cont, then, 24 hr later, stimulated with
PMA plus ionomycin for 0-8 hr. Error bars indicate SD. Data are representative of three independent experiments.
(C) Quantitative PCR analysis of mRNAs encoding c-Rel, Ox40, Il2, and IkBa in Jurkat cells electroporated as in (E), stimulated for 4 hr with PMA plus ionomycin,
and then treated for 0–4 hr with actinomycin D (ActD). Error bars indicate SD. Data are representative of three independent experiments.
(D) Jurkat cells were electroporated with wild-type or D141N Regnase-1 or mock and then stimulated with PMA plus ionomycin for 4 hr. Gene expression was
measured by quantitative PCR. Error bars indicate SD. Data are representative of two independent experiments.
(legend continued on next page)
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Regnase-1 Is Cleaved and Degraded in a Malt1-
Dependent Manner
Then we investigated the change in Regnase-1 expression in
T cells. Stimulation of Th1 cells with IL-18, which activates
signaling pathways overlapping with those of TLR/IL-1R,
induced the disappearance of Regnase-1 expression (Figure 5A).
Treatment with a proteasome inhibitor, MG132, resulted in the
suppression of Regnase-1 degradation, suggesting that the
MyD88-dependent signaling induces degradation of Regnase-1
in T cells in a manner similar to that in macrophages. In addition,
stimulation of naive CD4+ T cells with anti-CD3ε plus anti-CD28
antibodies or PMA plus ionomycin led to the reduction in Reg-
nase-1 (Figures 5B and 5C), although the decrease of Reg-
nase-1 was not inhibited by MG132 treatment (Figure 5D).
Furthermore, coculture of OT-II+ T cells with OVA-pulsed DCs
resulted in the decrease in Regnase-1 expression (Figure 5E).
These results indicate that the TCR signaling decreases Reg-
nase-1 expression independent of the IKK-dependent mecha-
nisms or the proteasome system. In contrast, TCR stimulation
led to the appearance of a protein smaller than full-length Reg-
nase-1 that was detected by anti-Regnase-1 antibody 15 min
after PMA and ionomycin stimulation (Figure 5F). Stimulation of
Regnase-1/CD4+ T cells with PMA and ionomycin did not pro-
duce the small protein (Figure 5F), suggesting that TCR signaling
leads to the cleavage of Regnase-1. The change in Regnase-1
expression was induced by PMA, but not ionomycin alone (Fig-
ure 5G). Given the fact that PMA activates the complex of
Carma1, Bcl10, and Malt1, also known as paracaspase, down-
stream of PKCq for activating NF-kB (Thome, 2008), we exam-
ined the involvement of this complex in the decrease of
Regnase-1. Interestingly, Bcl10/ or Malt1/ CD4+ T cells
stimulated with PMA and ionomycin did not decrease Reg-
nase-1 or generate cleaved protein (Figures 5H and 5I). In addi-
tion, treatment of Jurkat cells with zVRPR-fmk, a compound
inhibiting the protease activity of Malt1, prevented the degrada-
tion of Regnase-1 (Figure 5J). Furthermore, degradation of Reg-
nase-1 induced by anti-CD3ε plus anti-CD28 antibodies in CD4+
T cells was also suppressed by zVRPR-fmk treatment (Fig-
ure 5K). These results indicate that Regnase-1 is degraded in a
manner dependent on the protease activity of Malt1. Of note,
the Malt1 inhibitor failed to suppress IL-18-mediated degrada-
tion of Regnase-1 in CD4+ T cells (Figure 5A), indicating that
the mechanism of Regnase-1 degradation in T cells is different
depending on the stimuli.
Malt1-Mediated Regnase-1 Cleavage Increases
Stability of c-Rel, Ox40, and Il2 mRNAs in T Cells
Then we transfected HEK293 cells with an N-terminal Flag-
tagged and a C-terminal HA-tagged Regnase-1-expressing
plasmid, together with Malt1 and Bcl10. Cotransfection of Reg-
nase-1 with Bcl10 and Malt1 in HEK293 cells led to the cleavage(E) HEK293 tet-off cells were cotransfected with pTREtight-Il2, pTREtight-Ox40, o
Regnase-1 expression plasmid or control (empty) plasmid. Total RNAwas prepare
northern blot analysis. Representative data of two independent experiments are
(F) Luciferase activity of HEK293 cells transfected for 48 hr with luciferase reporter
type or D141N Regnase-1. Error bars indicate SD. Data are representative of tw
(G) Predicted stem-loop structure of the Regnase-1-responsive element in the 3
1044 Cell 153, 1036–1049, May 23, 2013 ª2013 Elsevier Inc.of Regnase-1, producing an 15 kDa N-terminal and 55 kDa
C-terminal fragments (Figure 6A). A fusion protein comprised
of the N terminus of inhibitor of apoptosis 2 (API2) and the C ter-
minus of Malt1 (API2-Malt1) generated in MALT lymphoma by a
translocation is proteolytically active to cleave NF-kB-inducing
kinase (NIK) (Rosebeck et al., 2011). Coexpression of Reg-
nase-1 and API2-Malt1 resulted in the generation of similar frag-
ments (Figure 6B). These findings suggest that Malt1 cleaves
Regnase-1 at a single site. Because Malt1 is an arginine-specific
protease, we expressed mutant Regnase-1 constructs whose
arginine residues present in the N terminus (R111, R130, R136,
R158, and R214) (Figure 6C) were substituted with alanine
together with Flag-tagged API2-Malt1 in HEK293 cells. We found
that Regnase-1 with substitution of alanine for arginine at posi-
tion 111 (R111A) was resistant to API2-Malt1-mediated cleav-
age, although other mutant Regnase-1 proteins were cleaved
by API2-Malt1 (Figure 6B). These results indicated that Reg-
nase-1 is cleaved at the site of R111 by Malt1. Consistently,
wild-type, but not R111A, Regnase-1 was degraded 30 min after
PMA/ionomycin stimulation in Jurkat cells (Figure 6D), indicating
that cleavage of Regnase-1 by Malt1 at R111 is critical for
inducing Regnase-1 degradation in response to TCR stimulation.
To further investigate the role of Malt1 protease activity in con-
trolling mRNA stability, primary CD4+ T cells pretreated with
zVRPR-fmk were stimulated with PMA/ionomycin, and the
kinetics of mRNA degradation was examined after stopping
new transcription. As shown in Figure 6E, mRNAs for c-Rel,
Ox40, and Il2, but not mRNA for IkBa, were destabilized in
response to treatment with the Malt1 inhibitor, indicating that
the Malt1 protease activity is critical for increasing the stability
of a set of mRNAs. Finally, we examined whether cleavage of
Regnase-1 in T cells is induced in vivo in response to antigen
stimulation. When OT-II mice harboring TCR specific to OVA
were immunized with OVA together with alum adjuvant, Reg-
nase-1 levels decreased and cleaved products increased in
CD4+ T cells 12 hr after immunization (Figure 6F). The immuniza-
tion resulted in no cleavage of Regnase-1 in CD4+ T cells from
nontransgenic animals, indicating that TCR signaling is required
for the cleavage of Regnase-1.
DISCUSSION
We have previously shown that Regnase-1 controls Il6 and Il12b
mRNA via their 30 UTR (Matsushita et al., 2009). However, lack of
IL-6 and IL-12p40 only modestly rescued aberrant plasma cell
development and Th1 induction, respectively. In contrast,
T cells lacking Regnase-1 were spontaneously activated and
showed effector/memory phenotype. It is noteworthy that mice
lacking Regnase-1 in macrophages and neutrophils also devel-
oped a fatal inflammatory disease (data not shown), indicating
that Regnase-1 is essential for suppressing aberrant activationr pTREtight-c-Rel containing CDS plus 30 UTR together withwild-type or D141N
d after dox treatment, and Il2,Ox40, c-Rel, andActb levels were determined by
shown.
plasmids, together with control plasmid (Mock) or expression plasmid for wild-
o independent experiments.
0 UTR of c-Rel mRNA. See also Figure S5.
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Figure 5. Regnase-1 Is Cleaved and Degraded in a Malt1-Dependent Manner in T Cells
(A–K) Immunoblot analysis of Regnase-1, IkBa, and b-actin in whole-cell lysates from indicated cell types after treatment with indicated stimuli.
(A) Th1 cells were pretreated with 0.1% dimethyl sulfoxide (DMSO), the proteasome inhibitor MG-132 (10 mM), or theMalt1-specific inhibitor zVRPR-fmk (100 mM)
and then stimulated with IL-18 for 0–60 min.
(B and C) Wild-type CD4+ T cells were stimulated with anti-CD3ε plus anti-CD28 (B), or with PMA plus ionomycin (C) for the indicated time.
(D) Wild-type CD4+ T cells were pretreated with 0.1% DMSO or MG132 (10 mM) and then stimulated as in (C) for 0–60 min.
(E) CD4+ T cells were isolated from OT-II+ mice and cocultured with OVA-pulsed DC for indicated time.
(F) CD4+ T cells from CD4-Cre+ Regnase-1+/+ or CD4-Cre+ Regnase-1fl/fl mice were stimulated as in (C) for 0–60 min.
(G) Wild-type CD4+ T cells were stimulated with PMA, ionomycin, or both for 30 min.
(H and I) CD4+ T cells were prepared from wild-type and Bcl10/ (H), or Malt1/ mice (I) and then stimulated as in (C) for 0–60 min.
(legend continued on next page)
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of multiple immune cells in a cell-autonomous fashion. Treg cell
populations and T cell suppression activity were not impaired in
Regnase-1-deficient T cells, suggesting that Treg cells are not
the cause of the pathology in the absence of Regnase-1. Thymic
CD4 and CD8 single positive T cell populations and TCRb reper-
toires were similar in wild-type mice and mice with Regnase-1-
deficient T cells, suggesting that Regnase-1 is dispensable for
thymic T cell development. Therefore, it is likely that Regnase-1
controls the activation of naive to effector T cells peripherally in a
cell-autonomous manner. However, further studies are required
for assessing the role of Regnase-1 in thymic T cell negative/
positive selection.
The Regnase-1 nuclease domain has been reported to act as a
deubiquitinase for suppressing NF-kB activation in addition to its
nuclease activity (Liang et al., 2010). In contrast, we have previ-
ously shown that NF-kB activation in response to TLR4 stimula-
tion as well as IL-1R stimulation was comparable between
wild-type and Regnase-1-deficient macrophages (Matsushita
et al., 2009). Similarly, we did not observe an enhancement
in NF-kB-DNA binding activity in Regnase-1-deficient T cells
compared with wild-type cells (Figure S4G). These results indi-
cate that Regnase-1 is not critical for suppressing NF-kB, either
in macrophages or T cells. Thus, we believe that Regnase-1
functions as an RNase, degrading mRNAs downstream of the
TLR or TCR signaling pathways inducing activation of transcrip-
tion factors.
We identified a set of mRNAs upregulated in Regnase-1-defi-
cient T cells with transcriptome analysis. Becausemany transcrip-
tion factors and surface cytokine/chemokine receptors are highly
upregulated, both in naive and effector Regnase-1-deficient
T cells, it is assumed that there are many genes upregulated
secondarily, in addition to primarily regulated genes. The
complexity makes it difficult to clarify Regnase-1 target mRNAs
responsible for T cell activation. We found that c-Rel mRNA was
a unique target of Regnase-1 among NF-kB family members.
c-Rel has been shown to be involved in autoimmune diseases
(Campbell et al., 2000) and also contributes to differentiation into
Th1 cells (Hilliard et al., 2002). However, deletion of c-Rel failed to
completely block the T cell activation observed in Regnase-1/
mice. These results indicate that enhanced expression of c-Rel
alone cannot fully explain the phenotype of Regnase-1/ mice.
Regnase-1 is likely to control the expression of multiple genes
responsible for the development of autoimmune diseases.
T cells lacking Regnase-1 highly express IcosmRNA and pro-
tein on the cell surface. Indeed, ICOS seems to be one promising
Regnase-1 target for suppression (Figure S5B). This observation
is reminiscent of San/San mice, which harbor a point mutation in
Roquin gene (Yu et al., 2007). The mutant mice show follicular
T cells were expanded because of excess expression of ICOS.
However, the lack of ICOS under Regnase-1 deficiency failed
to rescue spontaneous activation of T cells and pathology
(data not shown), suggesting that Roquin and Regnase-1 control
T cell activation by different mechanisms.(J) Jurkat cells were stimulated with PMA plus ionomycin for 0–60 min in the abs
(K) CD4+ T cells were pretreated with Z-VRPR-fmk and then stimulated as in (B)
Arrows indicate a faster migrating form of Regnase-1. NS, nonspecific band. Da
See also Figure S6.
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induces IKK-mediated phosphorylation of Regnase-1, triggering
its degradation via the ubiquitin-proteasome system in macro-
phages and HeLa cells (Iwasaki et al., 2011). IL-18-induced
degradation of Regnase-1 was inhibited by a proteasome inhib-
itor, suggesting that MyD88-dependent signaling induces Reg-
nase-1 degradation in T cells via IKK activation. In contrast, the
change in Regnase-1 expression in response to the TCR
signaling was totally independent of the proteasome system.
We have previously shown that IKK activation by TNF stimulation
is not sufficient to induce degradation of Regnase-1 (Iwasaki
et al., 2011). Phosphorylation of Regnase-1 by IRAK1 down-
stream of MyD88 appears to be required for the phosphorylation
of Regnase-1 by IKKs. Thus, TCR-mediated activation of IKKs
might be insufficient to induce degradation of Regnase-1
because MyD88 and IRAK1 are dispensable for the TCR
signaling pathway.
We identified Malt1 as a protease responsible for Regnase-1
cleavage in response to TCR stimulation. Malt1 forms a complex
with Bcl10 andCARMA1 and plays an important role in activation
of NF-kB in T cells in response to TCR stimulation (Thome, 2008).
Several reports have identified Malt1 cleavage target proteins
that are involved in T cell activation. These include A20, Bcl10,
CYLD, and NIK (Coornaert et al., 2008; Rebeaud et al., 2008;
Rosebeck et al., 2011; Staal et al., 2011). Because A20 and
CYLD are deubiquitinases targeting K63-type polyubiquitin
chains and are responsible for suppressing NF-kB activation,
inactivation of A20 and CYLD by Malt1 is expected to potentiate
NF-kB activation. On the other hand, cleaved Bcl10 is highly
potent to signal. Nevertheless, treatment with Malt1 protease
inhibitor did not affect IkBa degradation in response to TCR stim-
ulation; although, the presence of Malt1 is required for IkBa
degradation (Figures 5H and 5I). In this regard, the protease
activity of Malt1 seems to play a supportive, but not essential,
role in NF-kB signaling. On the other hand, Malt1 protease activ-
ity is essential for TCR-mediated Reganse-1 degradation.
Treatment with the Malt1 protease inhibitor results in destabi-
lization of a set of mRNAs. These data indicate that Malt1 is
critical not only for activating NF-kB-mediated transcriptional
control but also for prolonging mRNA half-lives by cleaving
Regnase-1. Given that the Malt1 protease activity is critical for
controlling the stability of a set of TCR-inducible mRNAs, it is
tempting to speculate that themajor role of Malt1 protease activ-
ity is to regulate mRNA stability by cleaving Regnase-1.
We showed that Regnase-1 was cleaved by Malt1 at the
position R111. Because the position R111 is N-terminal to the
RNase domain, the C-terminal product of cleaved Regnase-1
is expected to be enzymatically active. Indeed, a luciferase
reporter assay revealed that a Regnase-1 construct correspond-
ing to the C-terminal part of cleaved protein is still potent to sup-
press gene expression via Il6 and c-Rel 30 UTRs, although the
deleted protein was less active thanwild-type Regnase-1 protein
(data not shown). However, the expression levels of cleavedence or presence of zVRPR-fmk.
for the indicated time.
ta are representative of two (E–K) or three (A–D) independent experiments.
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Figure 6. Protease Activity of Malt1 Is Critical for the Degradation of Regnase-1
(A) Immunoblot analysis of lysates of HEK293 cells transfected to express Flag- and HA-Regnase-1 and/or Myc-Malt1 or Myc-Bcl10 (above lanes), probed with
anti-Flag, anti-HA, or anti-Myc.
(B) Cleavage of mouse Regnase-1 in HEK293 cells transfected with Flag-tagged wild-type or a series of mutant Regnase-1 with substitution of alanine for
arginine, and/or Flag-API2-Malt1. N-terminal fragment of Regnase-1 was analyzed by immunoblot with anti-Flag antibody.
(C) Domain structure of mouse Regnase-1 and alignment of N-terminal RNase domain in mouse and human Regnase-1.
(D) Immunoblot analysis of Regnase-1 and b-actin in Jurkat cells transfected with the plasmids expressing wild or R111A Regnase-1, or control plasmid (Mock)
and then stimulated with PMA plus ionomycin.
(legend continued on next page)
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Regnase-1 protein were much less than those of the full-length
protein expressed in unstimulated cells, suggesting that the
cleaved protein is unstable and further degraded by a cellular
protease.
In summary, we have demonstrated that Regnase-1 is essen-
tial for suppressing an unwanted T-cell-mediated immune reac-
tion by targeting multiple mRNAs encoding transcription factors,
surface molecules, and cytokines. Dynamic regulation of Reg-
nase-1 by TCR signaling contributes to robust T cell activation.
Manipulation of Malt1-mediated Regnase-1 expression appears
to be an important control point for T-cell-mediated immune
responses in vivo.
EXPERIMENTAL PROCEDURES
Generation of Regnase-1-Floxed Mice
The targeting vector was constructed by inserting a 3.2 kb fragment containing
exons 4 to 6 of the Regnase-1 (Zc3h12a) gene flanked by loxP sites, 1.0 kb of a
30 sequence, 5.7 kb of a 50 sequence, and a neomycin (neo)-resistant gene
flanked by loxP sites into a pBluescript vector. The targeting vector was line-
arized and transfected into GSI-I embryonic stem (ES) cells by electroporation,
and G418-resistant clones were screened for homologous recombination by
PCR and Southern blot analysis. The ES cells were transiently transfected
with CMV-Cre to eliminate the neo gene. The successfully recombinated
clones were microinjected into blastocytes derived from C57BL/6 mice and
transferred to pseudopregnant females. Mating of chimeric male mice to
C57BL/6 female mice resulted in the transmission of the floxed allele to the
germline. The Regnase-1fl/+ mice were crossed with the indicated Cre-
expressing mice. See also Figure S2.
Mice
CD4-Cre, Mx-Cre, or OT-II TCR transgenic mice have been described previ-
ously (Barnden et al., 1998; Ku¨hn et al., 1995; Lee et al., 2001). c-Rel/,
Bcl10/, and Malt1/ mice were provided by S. Gerondakis, S. Morris, and
V.M. Dixit, respectively (Ko¨ntgen et al., 1995; Ruefli-Brasse et al., 2003; Xue
et al., 2003). All mice were housed under specific pathogen-free conditions.
All animal experiments were done with the approval of the Animal Research
Committee of the Research Institute for Microbial Diseases, Osaka University.
Plasmids, Antibodies, and Reagents
The plasmid expressing Regnase-1 has been described. Point mutations of
the gene encoding Regnase-1 (R111A, R130A, R136A, R158A, and R214A)
were made with the QuikChange II Site-Directed Mutagenesis Kit (Agilent
Technologies, Santa Clara, CA, USA). The complementary DNAs (cDNAs)
encoding Bcl10 and Malt1 were ligated to the vector pcDNA3.1(+)-Myc for
expression. Full-length 30 UTR of c-Rel (1–536) and 30 UTR of b-globin
(1–130), with or without a c-Rel 30 UTR (220–239) sequence, were inserted in
the pGL3 vector. c-Rel, Ox40, or Il2 CDS+30 UTR was inserted in pTREtight
vector (Clontech, Mountain View, CA, USA). Expression plasmid for Flag-
tagged API2-Malt1 was provided by L.M. McAllister-Lucas. Antibodies for
immunoblot analysis were as follows: anti-Flag (M2 [A8592]; Sigma-Aldrich,
St. Louis), anti-hemagglutinin (3724; Cell Signaling Technology, Danvers,
MA, USA), anti-c-Myc (M4439; Sigma-Aldrich), IkBa (C-21; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), and b-actin (C-11; Santa Cruz Biotech-
nology). Polyclonal rabbit antibody to Regnase-1 has been described previ-
ously. Anti-mouse CD3ε and CD28 were from BD Pharmingen (San Diego).
Actinomycin D, PMA, ionomycin, and OVA (A5503) were from Sigma-Aldrich.
Imject Alum was from Pierce (Rockford, IL, USA). I-Ad OVA helper peptide was
fromMBL. MG132 was from Calbiochem (Darmstadt, Germany). Z-VRPR-fmk(E) Quantitative PCR analysis of mRNAs encoding c-Rel, Ox40, Il2, and IkBa amo
followed by treatment for 0–4 hr with ActD. Error bars indicate SD.
(F) Immunoblot analysis of Regnase-1 and b-actin in CD4+ T cells from OT-II or
Data are representative of two (D and F), three (A and E), or five (B) independent
1048 Cell 153, 1036–1049, May 23, 2013 ª2013 Elsevier Inc.was from Alexis (Farmingdale, NY, USA). Poly I:C has been described. The
mouse IFN-g and ANA antibody ELISA kits were purchased fromR&DSystems
(Minneapolis, MN, USA) and Alpha Diagnostic (Owings Mills, MD, USA),
respectively.
Transfer of CD4+ T Cells
CD4+ T cells were isolated from CD4-Cre+ Regnase-1fl/+ and CD4-Cre+
Regnase-1fl/fl splenocytes using the autoMACS system. The cells were intra-
venously transfused into partially irradiated CD45.1+ mice. Three months after
the transfer, the mice were sacrificed for experiments. For inducible deletion of
Regnase-1, 8- to 12-week-old MxCre+Regnase-1fl/fl mice were intraperitone-
ally (i.p.) injected with 50 mg of poly I:C. We used Mx-Cre+ Regnase-1fl/fl
mice when we transferred unrecombinased CD4+ T cells into CD45.1+ mice
followed by injection with 50 mg of poly I:C per head.
Immunization and Recall Stimulation
CD62LhiCD44lo CD4+ T cells (1 3 106) from OT-II+ control and CD4-Cre+
Regnase-1fl/fl mice were adoptively transferred into CD45.1+ C57BL/6 mice.
The mice were immunized i.p. with 100 mg of OVA protein complexed to Imject
Alum (ThermoScientific, Rockford, IL, USA) at the day of transfer. At day 5 after
immunization, the mice were sacrificed. For in vitro recall responses, 3 3 105
splenocytes were stimulated with various doses of OVA323-339 peptide.
RNA Sequencing
Total RNA was prepared from fluorescence-activated cell sorting (FACS)-
sorted CD4+ T cells from CD4-Cre+ Regnase-1+/+ or CD4-Cre+ Regnase-1fl/fl
mice. For RNA sequencing, sample preparation was performed using the
TruSeq RNA Kit (Illumina, San Diego). cDNA cluster generation and
sequencing were carried out by cBot and HiSeq2000, respectively (Illumina).
For processing of RNA sequencing (RNA-seq) data, quality of RNA-seq tags
was checked using FASTQC. The 30 ends of tags were trimmed, and the 30
most 50 bases were mapped to the mouse genome (mm9). Mapping was
done using TopHat (v. 1.4.0) (Trapnell et al., 2009) and Bowtie (v. 0.12.7) (Lang-
mead et al., 2009). University of California Santa Cruz (UCSC) annotations of
transcripts were used for the initial mapping of tags to the transcriptome.
Tags that could be uniquely mapped with at most two mismatches were con-
verted to counts of tags per base in the genome, which were in turn used to
calculate reads per kilobase per million (RPKM) values for each transcript
(Mortazavi et al., 2008). In order to facilitate comparison of gene expression
levels between samples, RPKM values were normalized using quantile
normalization.
Statistical Analysis
All data are presented as mean and SD. Statistical analysis was performed
with the Student’s t test. Statistical significance was defined as a p value
of <0.05.
For further additional details about the experimental procedures, please
refer to the Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and two tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2013.04.034.
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